Results of this post-hoc analysis of the TARGET study demonstrated that patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor (TNF) inhibitors treated with sarilumab 150 mg or 200 mg every 2 weeks on a conventional synthetic disease-modifying antirheumatic drug (csDMARD) background achieved greater clinical responses compared with those treated with placebo, regardless of baseline disease activity. However, a greater sarilumab treatment effect was achieved by patients with higher baseline disease activity.
In this analysis of the TARGET study, a sustained clinically significant response was achieved by more patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response to, or intolerance of, tumor necrosis factor (TNF) inhibitors treated with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) versus those treated with placebo plus csDMARDs.
This post-hoc analysis showed that the efficacy of sarilumab was maintained or improved in patients with rheumatoid arthritis (RA) who switched or continued into the open-label EXTEND trial to receive sarilumab 200 mg every 2 weeks (q2w) after completion of the ASCERTAIN trial, with particularly increased efficacy occurring in those who initially received tocilizumab or sarilumab 150 mg q2w